...
GYRESMALL

Gyre Therapeutics, Inc.

HealthcareBiotechnology
$8.24
$0.00(-3.29%)
52W$6.11
$13.75
FinancialsValuationvs ARGX
Updated Mar 2, 12:00 AM
RSI60
RS Rating58/99
Beta1.31
Volatility85%
F-Score4/9
Mkt Cap$711M
CONSOLIDATING

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

CONSOLIDATING

Gyre Therapeutics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 58), indicating performance broadly in line with the market. Earnings growth of 371% provides fundamental context to the price action. Investors should exercise caution due to high volatility (85% annualized), which requires wider risk management.

Relative Strength
58
out of 99
Average
Trend Score
2/4
Minervini Criteria
CONSOLIDATING
Risk (Beta)
1.31
vs S&P 500
ABOVE MKT
52W Position
28%
from 52W low
Lower Half
Trend & Momentum Analysis

Trend Template (Minervini)

CONSOLIDATING2/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$7.77
50 SMA > 100 SMA$7.80
100 SMA > 150 SMA$7.73
150 SMA > 200 SMA$7.90

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$8.08+1.93%ABOVE
50 SMA$7.77+6.08%ABOVE
100 SMA$7.80+5.59%ABOVE
150 SMA$7.73+6.54%ABOVE
200 SMA$7.90+4.29%ABOVE

Price Performance

1D-3.3%
1W+1.1%
1M+2.6%
3M+6.3%
6M-0.5%
YTD+21.0%
1Y-29.0%
3Y+22.3%
52-Week Trading Range28% from low
$8.24
52W Low$6.11
52W High$13.75

Technical Indicators

RSI (14)NEUTRAL
59.8
305070
VCP ScoreWARM
6/10
Base depth: 26.6%

Risk Profile

Beta
1.31
52W Vol
85%
ATR
$0.37
Max DD (1Y)
-48%

Volume Analysis

Today
8
50D Avg
60.0K
Vol Ratio
0.00x
Liquidity
ILLIQUID

Earnings Momentum

Q4'24+76%
$-0.16
Q1'25-94%
$0.00
Q2'25-93%
$0.00
Q3'25+371%
$0.23
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+81.34%
5 Years:—
3 Years:+143.36%
TTM:+2.13%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+114.60%

Stock Price CAGR

10 Years:-33.00%
5 Years:-38.47%
3 Years:+22.34%
1 Year:-28.97%

Return on Equity

10Y Avg:-70.0%
5Y Avg:-83.4%
3Y Avg:-63.4%
Last Year:4.8%

Key Metrics

Market Cap$711M
Gross Margin96.3%
Net Margin11.4%
Piotroski F-Score4/9

More GYRE Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

GYRE vs ARGXARGXCANFAKTXABVX

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 58 meansGYRE outperformed 58% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 1.31 means 31% more volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 4/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 6/10 with WARM status.

Frequently Asked Questions

Is GYRE in an uptrend right now?

GYRE has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.

Is GYRE overbought or oversold?

GYRE's RSI (14) is 60. The stock is in neutral territory, neither overbought nor oversold.

Is GYRE outperforming the market?

GYRE has a Relative Strength (RS) Rating of 58 out of 99. GYRE is performing about average compared to the market.

Where is GYRE in its 52-week range?

GYRE is trading at $8.24, which is 60% of its 52-week high ($13.75) and 28% above its 52-week low ($6.11).

How volatile is GYRE?

GYRE has a Beta of 1.31 and 52-week volatility of 85%. It's more volatile than the S&P 500 - expect bigger swings.